news
Novartis announces new CEO
Novartis announces CEO Joseph Jimenez to retire from Novartis in…
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
List view / Grid view
Dr Vasant Narasimhan
news
Novartis plans head-to-head studies of Cosentyx versus Humira
Long-term analyses suggest Cosentyx may lead to higher responses than…
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
news
Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that…
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
news
Dr Vasant Narasimhan elected a member of the US National Academy of Medicine
The US National Academy of Medicine (NAM) recently announced the…
11 November 2015 | By Victoria White
The US National Academy of Medicine (NAM) recently announced the election of Dr Vasant “Vas” Narasimhan as a member of the Academy.
